Key Takeaways
- Baker Hughes (BKR) announced a significant acquisition of Chart Industries (GTLS) for $13.6 billion, anticipating $325 million in annual cost savings.
- Eli Lilly's (LLY) Jaypirca met its primary endpoint in a Phase 3 trial, signaling positive progress for the pharmaceutical giant.
- Royal Caribbean Cruises (RCL) exceeded Q2 2025 earnings estimates with an adjusted EPS of $4.38 and maintained its revenue guidance.
- Merck & Co (MRK) reported Q2 2025 adjusted EPS above estimates, despite a slight revenue miss, and announced job cuts aiming for $3 billion in restructuring savings.
Baker Hughes (BKR) is set to acquire Chart Industries (GTLS) for a substantial $13.6 billion in an all-cash deal, valued at $210 per share. This strategic move is expected to significantly boost Baker Hughes' growth and earnings per share, with the acquisition slated for completion by mid-2026. The company anticipates realizing $325 million in annual cost savings within three years post-acquisition, reinforcing its energy and industrial technology strategy.
In the pharmaceutical sector, Eli Lilly and Company (LLY) announced positive news regarding its drug Jaypirca, which successfully met its primary endpoint in a Phase 3 clinical trial. This development could pave the way for further advancements and potential market expansion for Lilly's oncology portfolio.
Royal Caribbean Cruises (RCL) delivered a strong performance in the second quarter of 2025, reporting an adjusted earnings per share (EPS) of $4.38, surpassing analyst estimates of $4.09. The cruise operator also posted $3.199 billion in passenger ticket revenue and a net income of $1.214 billion, while maintaining its revenue guidance for the full year.
Meanwhile, Merck & Co (MRK) reported its Q2 2025 earnings, with an adjusted EPS of $2.13, exceeding the estimated $2.03. Despite revenue coming in slightly below expectations at $15.81 billion against an estimated $15.87 billion, the company announced plans for job cuts as part of a restructuring effort. Merck anticipates these measures will lead to $3 billion in savings from the restructuring and adjusted its full-year sales guidance to between $64.3 billion and $65.3 billion, a slight revision from its previous outlook of $64.1 billion to $65.6 billion.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.